Zydus Lifesciences rose 1.13% to Rs 353 after the company announced that its board would consider a share buyback on May 20, 2022.
The board will also consider the results for FY22 and the final dividend on May 20, 2022.
Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
On a consolidated basis, the company’s net profit fell by 5.08% to Rs 500.40 crore on a 0.61% increase in operating income to Rs 3,655 crore in Q3 FY22 compared to Q3 FY21 .
Powered by Capital Market – Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and up-to-date with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.
As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.
Support quality journalism and subscribe to Business Standard.